



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Guy A. Rouleau et al.

Serial No.: 10/664,603


Filed: September 17, 2003

For: LOCI FOR IDIOPATHIC GENERALIZED
EPILEPSY, MUTATIONS THEREOF
AND METHOD USING SAME TO
ASSESS, DIAGNOSE, PROGNOSIS OR
TREAT EPILEPSY

Group Art Unit: 1639

Examiner: Sue Xu Liu

Atty. Dkt. No.: GOUD:023USD1

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on the date below:	
April 21, 2006	
Date	Michael R. Krawczenski

STATEMENT AS REQUIRED UNDER 37 C.F.R. § 1.825(a) AND (b)
AND STATEMENT AS REQUIRED UNDER 37 C.F.R. § 1.821(g)

MAIL STOP SEQUENCE


Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Commissioner:

Submitted herewith is a substitute computer readable form and a substitute paper copy of the sequence listing of those sequences in the captioned patent application, wherein minor errors have been corrected. The substitute computer readable form of the sequence listing is the same as the substitute paper copy of the sequence listing. The sequence information provided in the Specification is also the same as the sequence listing of the enclosed substitute computer readable and paper forms of the sequence listing.

In accordance with 37 C.F.R. § 1.821(g), it is herewith represented that no new matter is included with this submission.

Respectfully submitted,



Michael R. Krawzsenek

Reg. No. 51,898

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 536-3020
(512) 536-4598 Facsimile

Date: April 21, 2006



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Guy A. Rouleau et al.

Serial No.: 10/664,603

Filed: September 17, 2003

For: LOCI FOR IDIOPATHIC GENERALIZED
EPILEPSY, MUTATIONS THEREOF
AND METHOD USING SAME TO
ASSESS, DIAGNOSE, PROGNOSIS OR
TREAT EPILEPSY

Group Art Unit: 1639

Examiner: Sue Xu Liu

Atty. Dkt. No.: GOUD:023USD1

CERTIFICATE OF MAILING

37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on the date below.

April 21, 2006

Date

Michael R. Krawzsenek

**TRANSMITTAL OF MATERIAL SUBMITTED ON A COMPACT DISC AND
STATEMENT AS REQUIRED UNDER 37 C.F.R. § 1.52(e)**

MAIL STOP SEQUENCE

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450


Commissioner:

Submitted herewith on a compact disc labeled "Copy 1" is the substitute Sequence Listing in computer readable form of the captioned patent application. Also submitted herewith is a duplicate copy of the compact disc labeled "Copy 2." Each of Copy 1 and Copy 2 contain one 324 kb file entitled "GOUD:023USD1.txt" and were created on April 21, 2006, in PC format using MS Windows operating system. Copy 1 and Copy 2 are identical.

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 536-3020
(512) 536-4598 Facsimile

Date: April 21, 2006

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Michael R. Krawzsenek", written over the typed name.

Michael R. Krawzsenek
Reg. No. 51,898
Attorney for Applicants



Notice to Comply	Application No. 10664603	Applicant(s) ROULEAU ET AL.	
	Examiner Sue Liu	Art Unit 1639	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: The instant Drawing and Specification (e.g. See pages 52 and 53) recite sequences, which are NOT in compliance with Sequence Rule. Reference to sequences in both specification and claims must be accompanied by proper sequence identifier, i.e. SEQ ID Nos. Applicants are requested to amend the instant specification and drawings accordingly.

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.**
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-2510
For CRF Submission Help, call (571) 272-2501/2583.
PatentIn Software Program Support
 Technical Assistance.....703-287-0200
 To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY